<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03073239</url>
  </required_header>
  <id_info>
    <org_study_id>2</org_study_id>
    <nct_id>NCT03073239</nct_id>
  </id_info>
  <brief_title>Amyotrophic Lateral Sclerosis: a New Paradigm</brief_title>
  <acronym>ALSParadigm</acronym>
  <official_title>Amyotrophic Lateral Sclerosis: a New Paradigm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Conde, Bebiana, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Conde, Bebiana, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic Lateral Sclerosis (ALS) is a degenerative neuromuscular disease, progressing
      inexorably to respiratory failure, the by involvement of respiratory muscles, the commitment
      with most impact on the prognosis of ALS.

      According to current knowledge, the clinical presentation of the disease is characterized by
      spinal or bulbar involvement, the latter being associated with a worse prognosis.

      There are multiple factors described in the aetiology of ALS, as the successive damage the
      motor neuron, which can happen in high-impact athletes, or exposure to heavy metals. Genetic
      mutations are also described, being associated to a higher prevalence of ALS.

      Data from retrospective studies with ALS populations reveal a prevalence of 4-8 cases per
      100,000 persons. Research carried out in Trás-os-Montes e Alto Douro region (Northeast of
      Portugal) shows a high prevalence of ALS, with near 10 cases per 100,000 persons, with a
      recent increase in the bulbar involvement. The reasons for the high prevalence of ALS in this
      region are unknown.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this research is to pursue potentially involved genetic mutations in this
      disease (new or previously described), in addition to carry out a epidemiological
      questionnaire including data on personal history, environmental and occupational exposure
      that might be underlying this high prevalence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Finding environmental risk factor</measure>
    <time_frame>2 years</time_frame>
    <description>Apply epidemiogycal form to All ALS patients sentido to respiratory evaluation in 2 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regional prevalence</measure>
    <time_frame>1 year</time_frame>
    <description>Identify All cases ALS in regional area ( in north of Portugal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Finding a genetic marker</measure>
    <time_frame>2 years</time_frame>
    <description>Scan all ALS patients to eventually finding new ALS genes</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>ALS epidemiological characterization</arm_group_label>
    <description>epidemiological characterization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genetic findings in ALS patients</arm_group_label>
    <description>genética characterization</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ALS patients genetic characterization</intervention_name>
    <description>Genetic findings in ALS patients</description>
    <arm_group_label>Genetic findings in ALS patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ALS patients epidemiological caracterization</intervention_name>
    <description>Epidemiological characterization in ALS patients</description>
    <arm_group_label>ALS epidemiological characterization</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood to test als mutations
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Amyotrophic Lateral Sclerosis sent to a medical consultation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with Amyotrophic Lateral Sclerosis sent to a medical consultation

        Exclusion Criteria:

          -  Amyotrophic Lateral Sclerosis not confirmed

          -  Ages less than 18 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bebiana Conde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Hospitalar Tras-os-Montes e Alto Douro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Hospitalar Tras-os-Montes e Alto Douro</name>
      <address>
        <city>Vila Real</city>
        <zip>5000</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>March 26, 2016</study_first_submitted>
  <study_first_submitted_qc>March 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2017</study_first_posted>
  <last_update_submitted>July 19, 2018</last_update_submitted>
  <last_update_submitted_qc>July 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Bulbar disfunction</keyword>
  <keyword>Rik factors ALS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Research results will be shared with the scientific community through the publication of 2 to 3 papers in medical journals, as well as through the participation in national and international conferences. Whenever requested by the participants, the individual data resulting from clinical examinations will be provided.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

